The largest addiction pharmacotherapy ever developed
A class of medications born from the treatment of diabetes and obesity has begun whispering something unexpected to the medical world: that the same molecules quieting hunger may also quiet the pull of addiction. Patients taking GLP-1 receptor agonists like semaglutida and tirzepatida are reporting dramatic reductions in their desire to drink alcohol, prompting researchers to ask whether a drug already in millions of hands might hold an answer to one of humanity's oldest afflictions. The science has not yet caught up with the observation, but the question itself — sitting at the crossroads of metabolism, neuroscience, and addiction — is now too loud to ignore.
- Millions of people already taking weight-loss injections are quietly reporting a side effect no one designed for: the urge to drink alcohol is fading, sometimes disappearing entirely.
- With alcohol linked to three million deaths per year globally and existing treatments falling short for many, the pressure to find new pharmacological tools is acute and urgent.
- Brain imaging from a Danish clinical trial shows that GLP-1 users experience measurably less activation in addiction-related brain regions when exposed to alcohol cues — suggesting this is biology, not coincidence.
- Researchers are racing to separate compelling anecdote from confirmed medicine, with multiple large-scale randomized trials now underway to test safety and efficacy for alcohol use disorder.
- If the trials succeed, these drugs — already among the most widely prescribed in the world — could become the largest addiction pharmacotherapy ever deployed, reshaping treatment on a global scale.
Megan Johnston, a 38-year-old real estate agent, began taking semaglutida last year to address weight gained during the pandemic. She had also been drinking more than fifteen alcoholic beverages a week. Within months, something she hadn't anticipated occurred: her desire to drink nearly disappeared. By her own account, her alcohol consumption fell by seventy-five percent, with some weeks passing without a single drink.
Hers is not an isolated story. Physicians and patients across the United States have begun noticing the same pattern among users of GLP-1 receptor agonists — a drug class that includes semaglutida, sold as Ozempic and Wegovy, and tirzepatida, sold as Mounjaro. Originally developed for type 2 diabetes and later found to produce significant weight loss, these medications now appear to suppress alcohol cravings as well. The scientific community, however, has not yet confirmed whether they are safe or effective for treating alcohol use disorder specifically.
The stakes are considerable. Alcohol contributes to three million deaths annually worldwide, and current treatment options leave many people without adequate help. Kyle Simmons, director of the Biomedical Imaging Center at Oklahoma State University, has noted that if these drugs prove effective for addiction, they would instantly become the largest addiction pharmacotherapy ever developed — simply because so many people already take them.
A 2022 Danish study offered some of the most compelling early evidence. Nearly 130 people with alcohol use disorder were enrolled, with some receiving semaglutida alongside cognitive-behavioral therapy and others receiving a placebo with therapy. Both groups reduced their drinking, but the GLP-1 group showed a dramatically steeper decline. Brain imaging revealed that when participants viewed images of alcohol, addiction-related brain regions activated far less intensely in those taking the drug — a finding that points toward a genuine neurobiological mechanism.
Researchers at the University of North Carolina have argued that the flood of social media reports from patients noticing reduced alcohol cravings deserves serious scientific attention, suggesting these accounts point toward mechanisms involving satiety, craving suppression, and altered reward response. Still, the Danish study's authors had prior ties to the pharmaceutical companies involved, and the field still lacks the large, rigorous trials needed to establish these drugs as a legitimate treatment. Several such trials are now underway. What began as an unexpected observation in patient reports now stands as one of medicine's more tantalizing open questions — unproven, but impossible to dismiss.
Megan Johnston, a 38-year-old real estate agent in the United States, had gained ten kilos during the pandemic and found herself drinking more than fifteen alcoholic beverages each week. Last year, she began taking semaglutida, an injectable medication originally developed to help people lose weight. Within months, something unexpected happened: her desire to drink alcohol nearly vanished. Some weeks she consumed nothing at all. By her own measure, her alcohol intake dropped by seventy-five percent.
Johnston is not alone. Doctors and patients across the country have begun noticing the same peculiar side effect among people using GLP-1 receptor agonists—a class of drugs that includes semaglutida (marketed as Ozempic and Wegovy) and tirzepatida (Mounjaro). These medications were originally designed to treat type 2 diabetes. Clinical trials later revealed they also produced significant weight loss. Now, anecdotal reports suggest they may also suppress the urge to drink alcohol, though the scientific community has not yet confirmed whether they are safe or effective for treating alcohol use disorder.
The potential implications are staggering. Kyle Simmons, director of the Biomedical Imaging Center at Oklahoma State University and a professor of pharmacology and physiology, has stated plainly that if these drugs prove both safe and effective for alcohol addiction, they would become the largest addiction pharmacotherapy ever developed—simply because millions of people already take them for weight loss. The mechanism appears to involve how semaglutida affects the brain, seemingly eliminating the pleasure associated with drinking. But the evidence remains preliminary. A case report published by Simmons's team in November documented six patients who received semaglutida and experienced significant reductions in alcohol use disorder symptoms, yet the researchers acknowledged that randomized, placebo-controlled clinical trials are still needed to fully evaluate the drug's efficacy.
The urgency of finding new treatments is real. According to the World Health Organization, alcohol consumption contributes to three million deaths annually worldwide and causes disability and poor health for millions more. Current treatment options are limited, and many people struggle to find effective help. This context has prompted researchers to take seriously what patients and doctors have been observing on social media and in clinical practice. Michael Bremmer and Christian Hendershot, researchers at the University of North Carolina at Chapel Hill, recently published an article in the Journal of Studies on Alcohol and Drugs arguing that social media comments from people taking weight-loss drugs and reporting changes in their alcohol consumption deserve scientific attention. These anecdotes, they suggest, not only justify launching clinical trials but also point toward possible neurobiological mechanisms—satiety, reduced cravings, aversion, altered subjective response—that could guide future neuroscience research.
One significant study came from Danish researchers in 2022. They enrolled nearly 130 people with alcohol use disorder and tested whether those receiving Ozempic combined with cognitive-behavioral therapy drank less than those receiving placebo and therapy alone. Both groups reduced their alcohol consumption, but the patients treated with the GLP-1 drug and therapy showed a dramatic decrease compared to the placebo group. Brain imaging of some participants revealed that when they viewed images of alcohol, the regions of the brain associated with addiction lit up far less intensely in those taking the GLP-1 compound, according to Anders Fink-Jensen, a psychiatry professor at the University of Copenhagen and a coauthor of the study.
Yet significant questions remain unanswered. The Danish study involved researchers who had previously received funding from the pharmaceutical companies that manufacture these drugs, raising questions about potential bias. More importantly, the field lacks the large-scale, rigorous clinical trials necessary to establish whether these medications are truly safe and effective for alcohol use disorder as a primary indication. Several such trials are currently underway, and the results will determine whether what began as an unexpected observation in patient reports becomes standard medical practice. For now, the promise is real but unproven—a tantalizing possibility that sits at the intersection of obesity treatment and addiction medicine, waiting for science to catch up with anecdote.
Citações Notáveis
If this medication results in being safe and effective for treating addiction, it would become the largest addiction pharmacotherapy ever developed, simply because of how many people already take it for other reasons.— Kyle Simmons, Oklahoma State University
The brain regions related to addiction lit up far less intensely in those taking the GLP-1 compound when viewing alcohol images.— Anders Fink-Jensen, University of Copenhagen
A Conversa do Hearth Outra perspectiva sobre a história
Why would a drug designed for diabetes suddenly affect how someone wants to drink alcohol? That seems like it shouldn't be connected at all.
The drug works on the brain in ways that go far beyond blood sugar. It affects reward pathways, satiety signals, the whole system that tells you whether something feels good or necessary. Alcohol activates those same reward centers. If the medication dampens that signal, the craving simply doesn't show up.
So it's not that people are choosing to drink less. It's that the desire itself is being chemically suppressed.
Exactly. That's what makes it different from willpower or therapy alone. The brain imaging shows addiction-related regions lighting up much less when people on the drug see alcohol cues. It's a neurological shift, not a behavioral one.
But if it works, why aren't we already treating alcohol addiction with this drug?
Because anecdotes aren't proof. We have case reports, we have one decent clinical trial from Denmark, we have social media posts. What we don't have yet is the large, rigorous, placebo-controlled trials that would let doctors prescribe it with confidence. The field is being careful—as it should be.
What happens if the trials confirm it works?
Then you're looking at a medication that millions of people already take for weight loss suddenly becoming the most powerful addiction treatment we've ever had. The scale alone would be transformative. But that's still a conditional if.